his gel may treat blood cancer that affects skin

New York, Aug 7 (IANS) An investigational topical gel effectively treats patients with a rare type of blood cancer that affects the skin, results of a phase one trial show.

The topical drug, resiquimod gel, diminishes the damage caused by the tumour and may completely remove cancerous cells from sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma.

Currently, there is no cure for CTCL aside from a bone marrow transplant.

However, the new study shows that the topical gel can eliminate the cancerous cells.

“The results of the trial suggest that resiquimod is safely and effectively absorbed into the skin, and beyond diminishing treated lesions, also enhances the immune response, leading to healing of even untreated lesions,” said first author and principal investigator Alain Rook, professor at Perelman School of Medicine at University of Pennsylvania, Philadelphia, US.

“To our knowledge, this is the first topical therapy that can clear untreated lesions and lead to complete remission in some patients,” Rook noted.

The findings offer hope to patients who have not responded to other modalities, including certain types of topical chemotherapy and phototherapy.

In the trial, twelve patients who had previously undergone an average of six treatments for early stage CTCL were treated with topical resiquimod gel at varying doses and intervals.

Patients applied specified doses to some portions of the affected skin for 16 weeks.

However, some patients using a little higher dose showed a full clearing of all malignant cells after only eight weeks.

By the final evaluation, treated lesions were significantly improved in 75 percent of patients, and 30 percent saw full resolution in all treated lesions.

Unlike other treatments, resiquimod also improved untreated lesions, resulting in more than 50 percent improvement for more than 90 percent of patients.

Two participants, one of whom had been living with CTCL for more than 15 years without response to treatment, saw full eradication of the disease.

The study was published online in the journal Blood.


Leave a Reply

Please enter your comment!

The opinions, views, and thoughts expressed by the readers and those providing comments are theirs alone and do not reflect the opinions of www.mangalorean.com or any employee thereof. www.mangalorean.com is not responsible for the accuracy of any of the information supplied by the readers. Responsibility for the content of comments belongs to the commenter alone.  

We request the readers to refrain from posting defamatory, inflammatory comments and not indulge in personal attacks. However, it is obligatory on the part of www.mangalorean.com to provide the IP address and other details of senders of such comments to the concerned authorities upon their request.

Hence we request all our readers to help us to delete comments that do not follow these guidelines by informing us at  info@mangalorean.com. Lets work together to keep the comments clean and worthful, thereby make a difference in the community.

Please enter your name here